The JAZF1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HeLa cells harboring targeted disruption of the JAZF1 gene. This loss-of-function model enables detailed investigation of JAZF1, a zinc finger transcriptional corepressor that participates in nuclear receptor-mediated regulation of metabolic gene networks. By avoiding single-cell cloning, the polyclonal format preserves genetic diversity and reduces clonal artifacts, making it suited for population-level functional assays in an epithelial cell background.
HeLa cells, derived from HPV18-positive cervical adenocarcinoma, represent a widely employed immortalized human epithelial line with extensively documented growth characteristics and signaling responses. Their well-characterized sensitivity to metabolic and oncogenic perturbations, combined with ease of genetic manipulation, provides a robust platform for cancer research. In this JAZF1 knockout context, the specific contributions of the corepressor to epithelial metabolism and tumor-associated behaviors can be directly probed without the confounding influence of clonal selection.
JAZF1 functions as a transcriptional corepressor by directly interacting with the TR4 nuclear receptor and recruiting histone deacetylase (HDAC)-containing complexes such as N-CoR/SMRT. This recruitment drives repression of key gluconeogenic enzymes (PCK1/PEPCK, G6PC/G6Pase) and lipogenic factors (FASN, ACACA), thereby coordinating glucose and lipid metabolism. Its activity is modulated by upstream signals including TR4 ligands, PPAR??, LXR, insulin, and the microRNA miR-141. Additionally, the JAZF1-SUZ12 fusion protein is a pathogenic driver in endometrial stromal sarcoma, underscoring JAZF1??s significance in both metabolic and oncogenic pathways.
Within HeLa cells, which endogenously express the TR4 nuclear receptor, N-CoR/SMRT components, and metabolic enzymes, JAZF1 knockout provides a powerful model to dissect corepressor-dependent metabolic reprogramming in epithelial cancer. Researchers can investigate how loss of JAZF1 alters insulin signaling, lipid accumulation, and glycolytic flux, and evaluate its impact on the epigenetic silencing of metabolic gene programs. The system also permits examination of the interplay between JAZF1 deficiency and HPV18-driven oncogenic processes, offering insights into metabolic vulnerabilities in cervical adenocarcinoma.
This polyclonal knockout product supports a broad range of applications, including functional genomic screens, metabolic flux analyses, and epigenetic profiling by ChIP-qPCR or RNA-seq. Standard validation via Western blotting and RT-qPCR can confirm JAZF1 ablation, followed by assessment of cell proliferation, apoptosis, migration, and invasion. The model is amenable to high-throughput drug screening targeting JAZF1-associated pathways and can serve as a surrogate for studying JAZF1-SUZ12 fusion biology. For further product information, please contact Ascent Research.
